Alkermes' ALKS 37 meets endpoint in Phase II opioid-induced bowel dysfunction trial
This article was originally published in Scrip
Executive Summary
Alkermes has reported positive preliminary results from a Phase II trial of ALKS 37, an orally active, peripherally restricted opioid antagonist for the treatment of opioid-induced bowel dysfunction (OBD). Alkermes said it plans to begin Phase III testing by the middle of this year.